H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $200 from $185 and keeps a Buy rating on the shares following the Q4 report. The Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease reported positive topline results, and the company is on track to submit a new drug application to the FDA in Q2, the analyst tells investors in a research note. The firm believes tinlarebant could win FDA approval in late 2026 or early 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
- Belite Bio price target raised to $217 from $187 at Benchmark
- Belite Bio price target raised to $201 from $191 at Morgan Stanley
- Belite Bio price target raised to $200 from $195 at BofA
- Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target